Valneva to Participate at U.S. and European Investor Conferences in June

Lyon (France), May 28, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings at several upcoming investor conferences in the United States and Europe in June 2026.

Key topics for discussion include Valneva’s commercial stage vaccines and its differentiated portfolio of vaccine candidates, including LB6V (formerly VLA15), the world’s leading Lyme Disease vaccine candidate. LB6V is partnered with Pfizer, who reported topline Phase 3 results demonstrating strong efficacy with no safety concerns. Pfizer is currently planning submissions to regulatory authorities.

Institutional investors who would like to meet 1on1 with management at any of the conferences below are asked to submit a request to their representative at the respective bank.

Jefferies Global Healthcare Conference

Format:                 Fireside chat and investor meetings
Date/ time:             June 3, 11:40am ET
Webcast:                 Link. A replay will be available in the “Investor” section of the Valneva website.
Location:                New York

Oddo BHF Nextcap Forum:

Format:                Investor meetings only
Date/ time:            June 12
Location                Virtual

BNP Paribas SMID Cap Conference:

Format:                Investor meetings only
Date/ time:            June 24
Location:               Paris, France

Additionally, the Company will also engage with travel medical professionals during a key European medical conference, where Valneva is a Gold Sponsor and Exhibitor.

10^th Northern European Conference on Travel Medicine (NECTM10)

Date/ time:                June 3 - 5
Location:                 Belfast, Ireland
Booth #:                4

Schreibe Deinen Kommentar